Evidence-based perspectives on the implementation of screening for neurocognitive impairment in HIV

References

• Anthony IC, Bell JE. The neuropathology of HIV/AIDS. Int Rev Psychiatry. 2008;20(1):15–24.
   PubMed Web of Science ®Google Scholar
• Price RW, Brew BJ. The AIDS dementia complex. J Infect Dis. 1988;158(5):1079–1083.
   PubMed Web of Science ®Google Scholar
• Bhaskaran K, Mussini C, Antinori A, et al; CASCADE Collaboration. Changes in the incidence and predictors of human immunodeficiency virus associated dementia in the era of highly active antiretroviral therapy. Ann Neurol. 2008;63(2):213–221.
   PubMed Web of Science ®Google Scholar
• Dore GJ, McDonald A, Li Y, Kaldor JM, Brew BJ; National HIV Surveillance Committee. Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS. 2003;17(10):1539–1545.
   Google Scholar
• Cysique LA, Maruff P, Brew BJ. Prevalence and pattern of neuropsychological impairment in HIV/AIDS infection across pre-HAART and HAART eras: a combined study of 2 cohorts. J Neurovirol. 2004;10(6):350–357.
   PubMed Web of Science ®Google Scholar
• Joska JA, Gouse H, Paul RH, Stein DJ, Flisher AJ. Does highly active antiretroviral therapy improve neurocognitive function? A systematic review. J Neurovirol. 2010;16(2):101–114.
   PubMed Web of Science ®Google Scholar
• Tozzi V, Balestra P, Libertone R, Antinori A. Cognitive function in treated HIV patients. Neurobehav HIV Med. 2010;2:95–113.
   Google Scholar
• Maki PM, Rubin LH, Valcour VG, et al. Cognitive function in women with HIV: findings from the Women’s Interagency HIV Study. Neurology. 2015;84(3):231–240.
   PubMed Web of Science ®Google Scholar
• McDonnell J, Haddow LJ, Daskalopoulou M, et al. Minimal cognitive impairment in UK HIV positive men who have sex with men: effect of case definitions, and comparison with the general population and HIV negative men. J Acquir Immune Defic Syndr. 2014;67(2):120–127.
   PubMed Web of Science ®Google Scholar
• Crum-Cianflone NF, Moore DJ, Letendre S, et al. Low prevalence of neurocognitive impairment in early diagnosed and managed HIV-infected persons. Neurology. 2013;80(4):371–379.
   PubMed Web of Science ®Google Scholar
• Heaton RK, Clifford DB, Franklin DRJ, et al; CHARTER Group. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology. 2010;75(23):2087–2096.
   PubMed Web of Science ®Google Scholar
• Simioni S, Cavassini M, Annoni JM, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS. 2010;24(9):1243–1250.
   PubMed Web of Science ®Google Scholar
• Bragança M, Palha A. Depression and neurocognitive performance in Portuguese patients infected with HIV. AIDS Behav. 2011;15(8):1879–1887.
   PubMed Web of Science ®Google Scholar
• Tozzi V, Balestra P, Lorenzini P, et al. Prevalence and risk factors for human immunodeficiency virus-associated neurocognitive impairment, 1996-2002: results from an urban observational cohort. J Neurovirol. 2005;11(3):265–273.
   Google Scholar
• Garvey LJ, Surendrakumar V, Winston A. Low rates of neurocognitive impairment are observed in neuro-asymptomatic HIV-infected subjects on effective antiretroviral therapy. HIV Clin Trials. 2011;12(6):333–338.
   PubMed Web of Science ®Google Scholar
• Winston A, Arenas-Pinto A, Stoehr W, et al. Neurocognitive function in HIV infected patients on antiretroviral therapy. PLoS One. 2013;8(4):e61949.
   PubMed Web of Science ®Google Scholar
• Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69(18):1789–1799.
   PubMed Web of Science ®Google Scholar
• Robertson KR, Smurzynski M, Parsons TD, et al. The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS. 2007;21(14):1915–1921.
   PubMed Web of Science ®Google Scholar
• Wright EJ, Grund B, Cysique LA, et al. Factors associated with neurocognitive test performance at baseline: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med. 2015;16(suppl 1):97–108.
   Google Scholar
• Ances BM, Hammoud DA. Neuroimaging of HIV-associated neurocognitive disorders (HAND). Curr Opin HIV AIDS. 2014;9(6):545–551.
   Web of Science ®Google Scholar
• Brew BJ, Letendre SL. Biomarkers of HIV related central nervous system disease. Int Rev Psychiatry. 2008;20(1):73–88.
   PubMed Web of Science ®Google Scholar
• Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection. Report of a Working Group of the American Academy of Neurology AIDS Task Force. Neurology. 1991;41(6):778–785.
   Google Scholar
• Gisslén M, Price RW, Nilsson S. The definition of HIV-associated neurocognitive disorders: are we overestimating the real prevalence? BMC Infect Dis. 2011;11:356.
   PubMed Web of Science ®Google Scholar
• Meyer AC, Boscardin WJ, Kwasa JK, Price RW. Is it time to rethink how neuropsychological tests are used to diagnose mild forms of HIV-Associated Neurocognitive Disorders? Impact of false-positive rates on prevalence and power. Neuroepidemiology. 2013;41(3–4):208–216.
   PubMed Web of Science ®Google Scholar
• Arenas-Pinto A, Winston A, Stohr W, et al. Neurocognitive function in HIV-infected patients: comparison of two methods to define impairment. PLoS One. 2014;9(7):e103498.
   PubMed Web of Science ®Google Scholar
• Ownby RL, Jacobs RJ, Waldrop-Valverde D, Gould F. Depression care and prevalence in HIV-positive individuals. Neurobehav HIV Med. 2010;2:73–83.
   Google Scholar
• Ciesla JA, Roberts JE. Meta-analysis of the relationship between HIV infection and risk for depressive disorders. Am J Psychiatry. 2001;158(5):725–730.
   PubMed Web of Science ®Google Scholar
• Kee MK, Lee SY, Kim NY, et al. Anxiety and depressive symptoms among patients infected with human immunodeficiency virus in South Korea. AIDS Care. 2015;27(9):1174–1182.
   PubMed Web of Science ®Google Scholar
• Robertson K, Bayon C, Molina JM, et al. Screening for neurocognitive impairment, depression, and anxiety in HIV-infected patients in Western Europe and Canada. AIDS Care. 2014;26(12):1555–1561.
   PubMed Web of Science ®Google Scholar
• Sewell MC, Goggin KJ, Rabkin JG, Ferrando SJ, McElhiney MC, Evans S. Anxiety syndromes and symptoms among men with AIDS: a longitudinal controlled study. Psychosomatics. 2000;41(4):294–300.
   PubMed Web of Science ®Google Scholar
• Keiser O, Spoerri A, Brinkhof MW, et al. Suicide in HIV-infected individuals and the general population in Switzerland, 1988-2008. Am J Psychiatry. 2010;167(2):143–150.
   PubMed Web of Science ®Google Scholar
• Scott-Sheldon LA, Walstrom P, Carey KB, Johnson BT, Carey MP, MASH Research Team. Alcohol use and sexual risk behaviors among individuals infected with HIV: a systematic review and meta-analysis 2012 to early 2013. Curr HIV/AIDS Rep. 2013;10(4):314–323.
   PubMed Web of Science ®Google Scholar
• Bourne A, Reid D, Hickson F, Torres-Rueda S, Weatherburn P. Illicit drug use in sexual settings (‘chemsex’) and HIV/STI transmission risk behaviour among gay men in South London: findings from a qualitative study. Sex Transm Infect. 2015;91(8):564–568.
   PubMed Web of Science ®Google Scholar
• Burdo TH, Katner SN, Taffe MA, Fox HS. Neuroimmunity, drugs of abuse, and neuroAIDS. J Neuroimmune Pharmacol. 2006;1(1):41–49.
   PubMed Web of Science ®Google Scholar
• Silverstein PS, Shah A, Weemhoff J, Kumar S, Singh DP, Kumar A. HIV-1 gp120 and drugs of abuse: interactions in the central nervous system. Curr HIV Res. 2012;10(5):369–383.
   Web of Science ®Google Scholar
• Rodger AJ, Lodwick R, Schechter M, et al. Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. AIDS. 2013;27(6):973–979.
   PubMed Web of Science ®Google Scholar
• Skingsley A, Kirwan P, Yin Z, et al. HIV New Diagnoses, Treatment and Care in the UK 2015 Report: Data to End 2014. London: Public Health England; 2015.
   Google Scholar
• Centers for Disease Control and Prevention. HIV Surveillance Report, 2014. Atlanta, GA: Centers for Disease Control and Prevention; 2015.
   Google Scholar
• Islam FM, Wu J, Jansson J, Wilson DP. Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis. HIV Med. 2012;13(8):453–468.
   PubMed Web of Science ®Google Scholar
• Sen S, Rabinstein AA, Elkind MSV, Powers WJ. Recent developments regarding human immunodeficiency virus infection and stroke. Cerebrovasc Dis. 2012;33:209–218.
   Web of Science ®Google Scholar
• Benjamin LA, Corbett EL, Connor MD, et al. HIV, antiretroviral treatment, hypertension, and stroke in Malawian adults: a case-control study. Neurology. 2016;86(4):324–333.
   Web of Science ®Google Scholar
• Wilson JMG, Jungner G. Principles and Practice of Screening for Disease. Geneva: World Health Organization; 1968.
   Google Scholar
• Tozzi V, Balestra P, Serraino D, et al. Neurocognitive impairment and survival in a cohort of HIV-infected patients treated with HAART. AIDS Res Hum Retroviruses. 2005;21(8):706–713.
   Web of Science ®Google Scholar
• Heaton RK, Marcotte TD, Mindt MR, et al. The impact of HIV-associated neuropsychological impairment on everyday functioning. J Int Neuropsychol Soc. 2004;10(3):317–331.
   PubMed Web of Science ®Google Scholar
• Woods SP, Iudicello JE, Moran LM, Carey CL, Dawson MS, Grant I. HIV-associated prospective memory impairment increases risk of dependence in everyday functioning. Neuropsychology. 2008;22(1):110–117.
   PubMed Web of Science ®Google Scholar
• Cysique LA, Waters EK, Brew BJ. Central nervous system antiretroviral efficacy in HIV infection: a qualitative and quantitative review and implications for future research. BMC Neurol. 2011;11:148.
   PubMed Web of Science ®Google Scholar
• Cole MA, Margolick JB, Cox C, et al. Longitudinally preserved psychomotor performance in long-term asymptomatic HIV-infected individuals. Neurology. 2007;69(24):2213–2220.
   PubMed Web of Science ®Google Scholar
• Sacktor N, Skolasky RL, Seaberg E, et al. Prevalence of HIV-associated neurocognitive disorders in the Multicenter AIDS Cohort Study. Neurology. 2016;86(4):334–340.
   PubMed Web of Science ®Google Scholar
• Cysique LA, Letendre SL, Ake C, et al. Incidence and nature of cognitive decline over 1 year among HIV-infected former plasma donors in China. AIDS. 2010;24(7):983–990.
   PubMed Web of Science ®Google Scholar
• Heaton RK, Franklin DR, Deutsch R, et al. Neurocognitive change in the era of HIV combination antiretroviral therapy: the longitudinal CHARTER study. Clin Infect Dis. 2015;60(3):473–480.
   PubMed Web of Science ®Google Scholar
• Haddow LJ, Pierce KJ, Daskalopoulou M, Lampe F, Rodger AJ. Neurocognitive change observed in the CHARTER HIV cohort could be due to chance, and may be a cause as well as a consequence of detectable viremia. Clin Infect Dis. 2015;60(9):1441–1442.
   Web of Science ®Google Scholar
• Ciccarelli N, Grima P, Fabbiani M, et al. Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2-year follow-up in HIV-infected patients. Antivir Ther. 2015;20(4):433–440.
   Web of Science ®Google Scholar
• Dufouil C, Richert L, Thiebaut R, et al. Diabetes and cognitive decline in a French cohort of patients infected with HIV-1. Neurology. 2015;85(12):1065–1073.
   PubMed Web of Science ®Google Scholar
• Becker BW, Thames AD, Woo E, Castellon SA, Hinkin CH. Longitudinal change in cognitive function and medication adherence in HIV-infected adults. AIDS Behav. 2011;15(8):1888–1894.
   PubMed Web of Science ®Google Scholar
• Grant I, Franklin DR Jr, Deutsch R, et al. Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline. Neurology. 2014;82(23):2055–2062.
   PubMed Web of Science ®Google Scholar
• Rourke SB, Gill J, Rachlis A, et al. Asymptomatic neurocognitive impairment (ANI) is associated with progression to symptomatic HIV-associated neurocognitive disorders (HAND) in people with HIV: results from The Ontario HIV Treatment Network (OHTN) cohort study. 8th IAS Conference on HIV Pathogenesis, Treatment & Prevention. Vancouver, BC: 2015.
   Google Scholar
• Williams IG, Churchill D, Anderson J, et al. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy. HIV Med. 2012;13(suppl 2):1–85.
   Google Scholar
• Reiss P, Battegay M, Clumeck N, et al. European AIDS Clinical Society Guidelines; Version 6 - October 2011. Paris: European AIDS Clinical Society; 2011.
   Google Scholar
• Lundgren JD, Babiker AG, Gordin F, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795–807.
   PubMed Web of Science ®Google Scholar
• Nightingale S, Michael BD, Defres S, Benjamin LA, Solomon T. Test them all; an easily diagnosed and readily treatable cause of dementia with life-threatening consequences if missed. Pract Neurol. 2013;13(6):354–356.
   Google Scholar
• Weber E, Blackstone K, Woods SP. Cognitive neurorehabilitation of HIV-associated neurocognitive disorders: a qualitative review and call to action. Neuropsychol Rev. 2013;23(1):81–98.
   PubMed Web of Science ®Google Scholar
• Letendre S, Marquie-Beck J, Capparelli E, et al. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol. 2008;65(1):65–70.
   PubMed Web of Science ®Google Scholar
• Shikuma CM, Nakamoto B, Shiramizu B, et al. Antiretroviral monocyte efficacy score linked to cognitive impairment in HIV. Antivir Ther. 2012;17(7):1233–1242.
   Web of Science ®Google Scholar
• Winston A, Duncombe C, Li PCK, et al. Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after 48 weeks in treatment-naive, HIV-1-infected individuals commencing cART? A randomized, controlled study. Clin Infect Dis. 2010;50(6):920–929.
   PubMed Web of Science ®Google Scholar
• Garvey LJ, Winston A, Walsh J, et al. HIV-associated central nervous system diseases in the recent combination antiretroviral therapy era. Eur J Neurol. 2011;18(3):527–534.
   Web of Science ®Google Scholar
• Tozzi V, Balestra P, Salvatori MF, et al. Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders. J Acquir Immune Defic Syndr. 2009;52:56–63.
   PubMed Web of Science ®Google Scholar
• Carvalhal A, Gill MJ, Letendre SL, et al. Central nervous system penetration effectiveness of antiretroviral drugs and neuropsychological impairment in the Ontario HIV Treatment Network Cohort Study. J Neurovirol. 2016;22(3):349–357.
   PubMed Web of Science ®Google Scholar
• Baker LM, Paul RH, Heaps-Woodruff JM, et al. The effect of central nervous system penetration effectiveness of highly active antiretroviral therapy on neuropsychological performance and neuroimaging in HIV infected individuals. J Neuroimmune Pharmacol. 2015;10(3):487–492.
   Web of Science ®Google Scholar
• Fabbiani M, Grima P, Milanini B, et al. Antiretroviral neuropenetration scores better correlate with cognitive performance of HIV-infected patients after accounting for drug susceptibility. Antivir Ther. 2015;20(4):441–447.
   Web of Science ®Google Scholar
• Caniglia EC, Cain LE, Justice A, et al. Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions. Neurology. 2014;83(2):134–141.
   PubMed Web of Science ®Google Scholar
• Ellis RJ, Letendre SL, Vaida F, et al. Randomized trial of central nervous system-targeted antiretrovirals for HIV-associated neurocognitive disorder. Clin Infect Dis. 2014;58(7):1015–1022.
   PubMed Web of Science ®Google Scholar
• Perez-Valero I, Bayon C, Cambron I, Gonzalez A, Arribas JR. Protease inhibitor monotherapy and the CNS: peace of mind? J Antimicrob Chemother. 2011;66(9):1954–1962.
   Web of Science ®Google Scholar
• Paton NI, Stöhr W, Arenas-Pinto A, et al. Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trial. Lancet HIV. 2015;2(10):e417–e426.
   PubMed Web of Science ®Google Scholar
• Antinori A, Clarke A, Svedhem-Johansson V, et al. Week 48 efficacy and central nervous system analysis of darunavir/ritonavir monotherapy versus darunavir/ritonavir with two nucleoside analogues. AIDS. 2015;29(14):1811–1820.
   Web of Science ®Google Scholar
• Winston A, Puls R, Kerr SJ, et al. Dynamics of cognitive change in HIV-infected individuals commencing three different initial antiretroviral regimens: a randomized, controlled study. HIV Med. 2012;13(4):245–251.
   PubMed Web of Science ®Google Scholar
• Gazzard BG, Balkin A, Hill A. Analysis of neuropsychiatric adverse events during clinical trials of efavirenz in antiretroviral-naive patients: a systematic review. AIDS Rev. 2010;12(2):67–75.
   PubMed Web of Science ®Google Scholar
• Pedrol E, Llibre JM, Tasias M, et al. Outcome of neuropsychiatric symptoms related to an antiretroviral drug following its substitution by nevirapine: the RELAX study. HIV Med. 2015;16(10):628–634.
   Web of Science ®Google Scholar
• Canestri A, Lescure FX, Jaureguiberry S, et al. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis. 2010;50(5):773–778.
   PubMed Web of Science ®Google Scholar
• Edén A, Fuchs D, Hagberg L, et al. HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment. J Infect Dis. 2010;202(12):1819–1825.
   PubMed Web of Science ®Google Scholar
• Peluso MJ, Ferretti F, Peterson J, et al. Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load. AIDS. 2012;26(14):1765–1774.
   PubMed Web of Science ®Google Scholar
• Rawson T, Muir D, Mackie NE, Garvey LJ, Everitt A, Winston A. Factors associated with cerebrospinal fluid HIV RNA in HIV infected subjects undergoing lumbar puncture examination in a clinical setting. J Infect. 2012;65(3):239–245.
   Web of Science ®Google Scholar
• Sacktor N, Miyahara S, Deng L, et al. Minocycline treatment for HIV-associated cognitive impairment: results from a randomized trial. Neurology. 2011;77(12):1135–1142.
   Web of Science ®Google Scholar
• Schifitto G, Zhong J, Gill D, et al. Lithium therapy for human immunodeficiency virus type 1-associated neurocognitive impairment. J Neurovirol. 2009;15(2):176–186.
   Web of Science ®Google Scholar
• Schifitto G, Zhang J, Evans SR, et al. A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment. Neurology. 2007;69(13):1314–1321.
   Web of Science ®Google Scholar
• Simioni S, Cavassini M, Annoni JM, et al. Rivastigmine for HIV-associated neurocognitive disorders: a randomized crossover pilot study. Neurology. 2013;80(6):553–560.
   Web of Science ®Google Scholar
• Schifitto G, Peterson DR, Zhong J, et al. Valproic acid adjunctive therapy for HIV-associated cognitive impairment: a first report. Neurology. 2006;66(6):919–921.
   PubMed Web of Science ®Google Scholar
• Power C, Selnes OA, Grim JA, McArthur JC. HIV dementia scale: a rapid screening test. J Acquir Immune Defic Syndr. 1995;8(3):273–278.
   Web of Science ®Google Scholar
• Davis HF, Skolasky RL Jr, Selnes OA, Burgess DM, McArthur JC. Assessing HIV-associated dementia: modified HIV dementia scale versus the Grooved Pegboard. AIDS Read. 2002;12(1):29–31.
   PubMedGoogle Scholar
• Haddow LJ, Floyd S, Copas A, Gilson RJ. A systematic review of the diagnostic accuracy of the HIV dementia scale and International HIV Dementia Scale. PLoS One. 2013;8(4):e61826.
   PubMed Web of Science ®Google Scholar
• Zipursky AR, Gogolishvili D, Rueda S, et al. Evaluation of brief screening tools for neurocognitive impairment in HIV/AIDS: a systematic review of the literature. AIDS. 2013;27(15):2385–2401.
   Web of Science ®Google Scholar
• Hu X, Zhou Y, Long J, et al. Diagnostic accuracy of the International HIV Dementia Scale and HIV dementia scale: a meta-analysis. Exp Ther Med. 2012;4(4):665–668.
   Web of Science ®Google Scholar
• Kamminga J, Cysique LA, Lu G, Batchelor J, Brew BJ. Validity of cognitive screens for HIV-associated neurocognitive disorder: a systematic review and an informed screen selection guide. Curr HIV/AIDS Rep. 2013;10(4):342–355.
   PubMed Web of Science ®Google Scholar
• Lijmer JG, Mol BW, Heisterkamp S, et al. Empirical evidence of design-related bias in studies of diagnostic tests. JAMA. 1999;282:1061–1066.
   PubMed Web of Science ®Google Scholar
• Levine AJ, Palomo M, Hinkin CH, et al. A comparison of screening batteries in the detection of neurocognitive impairment in HIV-infected Spanish speakers. Neurobehav HIV Med. 2011;3:79–86.
   Google Scholar
• Wojna V, Skolasky RL, McArthur JC, et al. Spanish validation of the HIV dementia scale in women. AIDS Patient Care STDS. 2007;21(12):930–941.
   Web of Science ®Google Scholar
• Kvalsund MP, Haworth A, Murman DL, Velie E, Birbeck GL. Closing gaps in antiretroviral therapy access: human immunodeficiency virus-associated dementia screening instruments for non-physician healthcare workers. Am J Trop Med Hyg. 2009;80(6):1054–1059.
   PubMed Web of Science ®Google Scholar
• Sacktor NC, Wong M, Nakasujja N, et al. The International HIV Dementia Scale: a new rapid screening test for HIV dementia. AIDS. 2005;19:1367–1374.
   PubMed Web of Science ®Google Scholar
• Nakasujja N, Skolasky RL, Musisi S, et al. Depression symptoms and cognitive function among individuals with advanced HIV infection initiating HAART in Uganda. BMC Psychiatry. 2010;10:44.
   Web of Science ®Google Scholar
• Joska JA, Westgarth-Taylor J, Hoare J, et al. Validity of the International HIV Dementia Scale in South Africa. AIDS Patient Care STDS. 2011;25(2):95–101.
   Web of Science ®Google Scholar
• Singh D, Sunpath H, John S, Eastham L, Gouden R. The utility of a rapid screening tool for depression and HIV dementia amongst patients with low CD4 counts – a preliminary report. Afr J Psychiatry (Johannesbg). 2008;11(4):282–286.
   Google Scholar
• Choi Y, Townend J, Vincent T, Zaidi I, Sarge-Njie R, Jaye A. Neurologic manifestations of human immunodeficiency virus-2: dementia, myelopathy, and neuropathy in West Africa. J Neurovirol. 2011;17(2):166–175.
   Web of Science ®Google Scholar
• Clifford DB, Mitike MT, Mekonnen Y, et al. Neurological evaluation of untreated human immunodeficiency virus infected adults in Ethiopia. J Neurovirol. 2007;13(1):67–72.
   PubMed Web of Science ®Google Scholar
• Birbeck GL, Kvalsund MP, Byers PA, et al. Neuropsychiatric and socioeconomic status impact antiretroviral adherence and mortality in rural Zambia. Am J Trop Med Hyg. 2011;85(4):782–789.
   PubMed Web of Science ®Google Scholar
• Waldrop-Valverde D, Nehra R, Sharma S, et al. Education effects on the International HIV Dementia Scale. J Neurovirol. 2010;16(4):264–267.
   Web of Science ®Google Scholar
• Jaeschke R, Guyatt GH, Sackett DL. Users’ guides to the medical literature. VI. How to use an article about a diagnostic test. B: What are the results and will they help me in caring for my patients? JAMA. 1994;271:703–707.
   PubMed Web of Science ®Google Scholar
• Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–198.
   PubMed Web of Science ®Google Scholar
• Skinner S, Adewale AJ, DeBlock L, Gill MJ, Power C. Neurocognitive screening tools in HIV/AIDS: comparative performance among patients exposed to antiretroviral therapy. HIV Med. 2009;10(4):246–252.
   PubMed Web of Science ®Google Scholar
• Joska JA, Witten J, Thomas KG, et al. A comparison of five brief screening tools for HIV-associated neurocognitive disorders in the USA and South Africa. AIDS Behav. 2016;20. Epub 2016 Feb 9.
   Web of Science ®Google Scholar
• Hasbun R, Eraso J, Ramireddy S, et al. Screening for neurocognitive impairment in HIV individuals: the utility of the Montreal Cognitive Assessment test. J AIDS Clin Res. 2012;3(10):186.
   PubMedGoogle Scholar
• Janssen MA, Bosch M, Koopmans PP, Kessels RP. Validity of the Montreal Cognitive Assessment and the HIV dementia scale in the assessment of cognitive impairment in HIV-1 infected patients. J Neurovirol. 2015;21(4):383–390.
   PubMed Web of Science ®Google Scholar
• Overton ET, Azad T, Parker N, et al. The Alzheimer disease-8 and Montreal Cognitive Assessment as screening tools for neurocognitive impairment in HIV-infected persons. J Neurovirol. 2013;19(1):109–116.
   Web of Science ®Google Scholar
• Milanini B, Wendelken LA, Esmaeili-Firidouni P, Chartier M, Crouch P-C, Valcour V. The Montreal Cognitive Assessment (MoCA) to screen for cognitive impairment in HIV over age 60. J Acquir Immune Defic Syndr. 2014;67(1):67–70.
   PubMed Web of Science ®Google Scholar
• Ku NS, Lee Y, Ahn JY, et al. HIV-associated neurocognitive disorder in HIV-infected Koreans: Korean NeuroAIDS Project. HIV Med. 2014;15(8):470–477.
   Web of Science ®Google Scholar
• Robbins RN, Joska JA, Thomas KGF, et al. Exploring the Utility of the Montreal Cognitive Assessment to detect HIV-associated neurocognitive disorder: the challenge and need for culturally valid screening tests in South Africa. Clin Neuropsychol. 2013;27(3):437–454.
   PubMed Web of Science ®Google Scholar
• Muñoz-Moreno JA, Prats A, Pérez-Álvarez N, et al. A brief and feasible paper-based method to screen for neurocognitive impairment in HIV-infected patients: the NEU screen. J Acquir Immune Defic Syndr. 2013;63(5):585–592.
   PubMed Web of Science ®Google Scholar
• Ellis RJ, Evans SR, Clifford DB, et al. Clinical validation of the NeuroScreen. J Neurovirol. 2005;11(6):503–511.
   PubMed Web of Science ®Google Scholar
• Fogel BS. The high sensitivity cognitive screen. Int Psychogeriatr. 1991;3(2):273–288.
   Google Scholar
• Cysique LAJ, Maruff P, Darby D, Brew BJ. The assessment of cognitive function in advanced HIV-1 infection and AIDS dementia complex using a new computerised cognitive test battery. Arch Clin Neuropsychol. 2006;21:185–194.
   PubMed Web of Science ®Google Scholar
• Gonzalez R, Heaton RK, Moore DJ, et al. Computerized reaction time battery versus a traditional neuropsychological battery: detecting HIV-related impairments. J Int Neuropsychol Soc. 2003;9(1):64–71.
   PubMed Web of Science ®Google Scholar
• Wu AW, Rubin HR, Mathews WC, et al. A health status questionnaire using 30 items from the Medical Outcomes Study. Preliminary validation in persons with early HIV infection. Med Care. 1991;29(8):786–798.
   PubMed Web of Science ®Google Scholar
• De Francesco D, Underwood J, Post FA, et al. Levels of agreement between commonly used definitions of cognitive impairment and the EACS screening questions in older HIV-positive subjects and matched controls. 15th European AIDS Conference; 21-24 October,2015. Barcelona: 2015.
   Google Scholar
• Muñoz-Moreno JA, Prats A, Nieto-Verdugo I, et al. Distinct detection of HIV-associated neurocognitive dysfunction according to clinician and patient perception: findings from the NEU study. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 17-20 July 2011. Rome: 2011.
   Google Scholar
• Fasel D, Kunze U, Elzi L, et al. A short tool to screen HIV-infected patients for mild neurocognitive disorders – a pilot study. BMC Psychol. 2014;2(1):21.
   Google Scholar
• Lundgren JD, Gatell JM, Rockstroh JK, Furrer H. European AIDS Clinical Society Guidelines. Huntingdon: EACS; 2015.
   Google Scholar
• MedFASH. British Psychological Society, British HIV Association & Medical Foundation for AIDS & Sexual Health. Standards for Psychological Support for Adults Living with HIV. London: MedFASH; 2011.
   Google Scholar
• Knippels HM, Goodkin K, Weiss JJ, Wilkie FL, Antoni MH. The importance of cognitive self-report in early HIV-1 infection: validation of a cognitive functional status subscale. AIDS. 2002;16(2):259–267.
   Web of Science ®Google Scholar
• Haddow LJ, Daskalopoulou M, McDonnell J, et al. Neuropsychological performance and self-reported function in HIV positive patients in five European clinics. 15th European AIDS Conference; 21-24 October, 2015. Barcelona: 2015.
   Google Scholar
• Nightingale A, Ratcliffe D, Leonidou L, et al. HIV-related neurocognitive impairment screening: the patient’s perspective on its utility and psychological impact. AIDS Care. 2014;26(8):1036–1041.
   PubMed Web of Science ®Google Scholar
• Ellis RJ, Badiee J, Vaida F, et al. Nadir CD4 is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS. 2011;25(14):1747–1751.
   PubMed Web of Science ®Google Scholar
• Cysique LA, Murray JM, Dunbar M, Jeyakumar V, Brew BJ. A screening algorithm for HIV-associated neurocognitive disorders. HIV Med. 2010;11(10):642–649.
   PubMed Web of Science ®Google Scholar